Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/aTyr Pharma, Inc./ 10-Q

Quarterly Report · 10-Q

aTyr Pharma, Inc.

Quarterly Report

Filed May 2, 2024Accepted May 2, 2024, 12:07 PM EDTCIK 1339970Accession 0000950170-24-052092
View company →Permanent SEC source ↗
Share

Company context

aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a novel biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.

Current securities

ATYRNASDAQ · EQUITY · Current
Historical securities (1)
ATYRNASDAQ · EQUITY · Historical · closed Oct 19, 2026

Recent company filings

  1. Results of Operations and Financial ConditionNov 5, 2026
  2. SCHEDULE 13G/A - filed by FEDERATED HERMES, INC. regarding aTYR PHARMA INCNov 4, 2026
  3. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearOct 27, 2026
  4. Submission of Matters to a Vote of Security HoldersOct 16, 2026
  5. SCHEDULE 13G/A - filed by FEDERATED HERMES, INC. regarding aTYR PHARMA INCOct 7, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.